Literature DB >> 12199676

Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders.

L S Diamondstone1, L M Aledort, J J Goedert.   

Abstract

Historically, the leading cause of death among persons with haemophilia and other congenital coagulation disorders was uncontrolled bleeding. Mortality was associated with severe deficiency of coagulation factors VIII or IX and especially with high-titre antifactor neutralizing antibodies (inhibitors). The catastrophic contamination of plasma donor pools with human immunodeficiency virus (HIV) resulted in acquired immunodeficiency syndrome replacing haemorrhage as the leading cause of death among persons with haemophilia. Rather little has been written, however, about mortality among those not infected with HIV. The objective of this study was to identify conditions associated with all-cause mortality among HIV-uninfected patients who were followed for a mean of 8.8 years in the Multicentre Hemophilia Cohort Study. Among the 364 children (mean age 8 years), there were four deaths; two related to cancer, one to trauma, and the fourth to haemorrhage, end-stage liver disease and sepsis. Among the 387 HIV-uninfected adults (mean age 35 years) there were 29 deaths, with haemorrhage the leading cause of death, followed by hepatic, stroke and cancer deaths. Prognostic factors for all-cause mortality among the adults included haemophilia Type A with neutralizing antibodies [age-adjusted relative rate (RR) 3.1, 95% confidence interval (CI) 1.4-6.9] and serologic evidence of both hepatitis B and C virus (RR 4.1, 95% CI 0.97-17.6). Although hepatitis C viral load was slightly lower in patients with hepatitis B virus surface antigenaemia, it was unrelated to vital status. We conclude that causes of death and prognostic factors for current HIV-uninfected haemophilia patients are similar to those noted before the HIV epidemic. Better understanding, prevention and control of neutralizing antibodies and hepatitis infections may substantially improve longevity for people with haemophilia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12199676     DOI: 10.1046/j.1365-2516.2002.00651.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance.

Authors:  Guy Young
Journal:  Blood Adv       Date:  2018-10-23

2.  Inhibitor clinical burden of disease: a comparative analysis of the CHESS data.

Authors:  Abiola O Oladapo; Mei Lu; Shaun Walsh; Jamie O'Hara; Teresa L Kauf
Journal:  Orphanet J Rare Dis       Date:  2018-11-09       Impact factor: 4.123

Review 3.  Mortality in congenital hemophilia A - a systematic literature review.

Authors:  Charles R M Hay; Francis Nissen; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.